Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29583693 | 1.00 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL154048 | 1.00 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| Hydrochloric Acid SCHEMBL27754570 | 0.99 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| Methoxymethane SCHEMBL27466715 | 0.97 | MRGPRX2 (0.94) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL10527174 | 0.90 | MRGPRX2 (0.82) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL8362208 | 0.90 | MRGPRX2 (0.81) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL8356924 | 0.88 | MRGPRX2 (0.79) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL5108263 | 0.88 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| SCHEMBL29459625 | 0.88 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL8168636 | 0.87 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119178875-A | Detection O6Test strip of monoacetylmorphine and methamphetamine and detection method | 重庆医科大学 | 2024-12-24 | — | — | CN | claimed |
| CN-119125344-A | Method for determining drugs in sewage by ultra-high performance liquid chromatography-tandem mass spectrometry and application thereof | 江苏省理化测试中心(江苏省理化测试技术研究所) | 2024-12-13 | — | — | CN | claimed |
| CN-115290803-A | LC-MS/MS qualitative and quantitative analysis method for 9 drugs in hair | 广州金域司法鉴定技术有限公司 | 2022-11-04 | — | — | CN | claimed |
| EP-4014051-A1 | HOMOGENEOUS ENZYME IMMUNOASSAY FOR KERATINIZED STRUCTURES | Psychemedics Corporation (US) | 2022-06-22 | — | — | EP | claimed |
| EP-3983127-A1 | PLASMA SEPARATION AND SAMPLE METERING DEVICE AND KITS AND METHODS OF USE RELATED THERETO | Siemens Healthcare Diagnostics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| CN-122031596-A | Application of compound preparation with effects of clearing away heart fire and soothing nerves in preparation of insomnia improving product | 中国中医科学院医学实验中心 | 2026-05-15 | — | — | CN | disclosed |
| US-12594330-B2 | Anti-opioid compounds and methods of making and using same | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4713957-A1 | DOUBLE SINGLE-ION MONITORING MASS SPECTROMETRY | Roche Diagnostics GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-12523669-B2 | Methods and systems for improved quality assurance for high-throughput analysis | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4627350-A1 | DETECTION OF AN ANALYTE OF INTEREST BY A CHIP BASED NANOESI DETECTION SYSTEM | F. Hoffmann-La Roche AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-12429484-B2 | Homogeneous enzyme immunoassay for keratinized structures | PSYCHEMEDICS CORPORATION (US) | 2025-09-30 | — | — | US | disclosed |
| US-12385919-B2 | — | — | 2025-08-12 | — | — | US | disclosed |
| US-20220296707-A1 | ANTI-OPIOID COMPOUNDS AND METHODS OF MAKING AND USING SAME | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2022-09-22 | — | — | US | disclosed |
| EP-4045035-A1 | TLR7/8 AGONISTS TO ENHANCE IMMUNE RESPONSES IN OPIOID USING INDIVIDUALS | Children's Medical Center Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4014051-A1 | HOMOGENEOUS ENZYME IMMUNOASSAY FOR KERATINIZED STRUCTURES | Psychemedics Corporation (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220120748-A1 | HOMOGENEOUS ENZYME IMMUNOASSAY FOR KERATINIZED STRUCTURES | PSYCHEMEDICS CORPORATION | 2022-04-21 | — | — | US | disclosed |
| EP-3983127-A1 | PLASMA SEPARATION AND SAMPLE METERING DEVICE AND KITS AND METHODS OF USE RELATED THERETO | Siemens Healthcare Diagnostics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022073099-A1 | METALIZED NANO COATED SWAB FOR TRACE DETECTION | GREEN BELTING INDUSTRIES LTD. (CA) | 2022-04-14 | — | — | WO | disclosed |
| US-20220080042-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220080042-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220080042-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | DNPEP, CRHBP, AANAT | MRGPRX2 347/4885OPRM1 11/4885OPRD1 30/4885 |
| US-12594330-B2 | Anti-opioid compounds and methods of making and using same | OPRD1, OPRK1, OPRL1 | MRGPRX2 854/4885OPRM1 4/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.